Objective-We aimed to analyze the association between hepatic steatosis and aortic valve sclerosis in the general population. Approach and Results-Cross-sectional data of 2212 men and women, aged 45 to 81 years, from the baseline examination of the population-based Study of Health in Pomerania (SHIP-0) were analyzed. Hepatic steatosis was primarily defined as the presence of a hyperechogenic ultrasound pattern of the liver. Aortic valve sclerosis was determined by echocardiography. In our sample, hepatic steatosis was present in 877 (39.7%) individuals. Among participants with hepatic steatosis, aortic valve sclerosis was more common (n=323; 36.8%) compared with participants without hepatic steatosis (n=379; 28.4%; P<0.001). After adjustment for potential confounders, individuals with hepatic steatosis had 33% higher odds of aortic valve sclerosis compared with those without hepatic steatosis (95% confidence interval, 6%-66%; P=0.014).
F at accumulation in the liver, referred to as hepatic steatosis, is a common finding in developed societies, with a prevalence of ≈30% in adults of the overall population. 1 Hepatic steatosis is tightly interrelated with metabolic disturbances, including an adverse lipid profile, reduced insulin sensitivity, and prevalent type 2 diabetes mellitus, as well as general adiposity. [2] [3] [4] [5] It is also correlated with classic cardiovascular risk factors (eg, high blood pressure) 6 and subclinical cardiovascular disease (CVD). 1, 7, 8 Individuals with hepatic steatosis have increased intima media thickness, 9 higher plaque burden of the carotid arteries, 8, 9 and a higher prevalence of calcified and noncalcified plaques in the coronary arteries compared with individuals without hepatic steatosis. 10 Thus, there is accumulating evidence suggesting that hepatic steatosis either directly contributes to cardiovascular morbidity or is a marker of increased CVD risk.
Sclerosis of the aortic valve is characterized by progressive fibrosis and, at a later stage, calcification of the aortic valve leaflet; its physiopathology shares some parallels with the general atherosclerosis process. 11 The prevalence of aortic valve sclerosis increases strongly with age and is ≈21% to 31% in individuals aged ≥65 years. [12] [13] [14] [15] Additional major risk factors include high dyslipidemia, hypertension, and smoking. 14, 15 Although often clinically asymptomatic, aortic valve sclerosis portends an increased risk for incident CVD and cardiovascular mortality. 12 Given accumulating evidence linking hepatic steatosis to subclinical CVD and vascular remodeling phenotypes, we aimed to assess whether hepatic steatosis is associated with aortic valve sclerosis after adjustment for relevant confounding factors.
Results
Among the total study sample of 2212 (1078 women; 48.7%) participants, the overall prevalence of hepatic steatosis and aortic valve sclerosis were 39.7% and 31.7%, respectively. Participants with hepatic steatosis were more likely to be men, to be inactive, to smoke, to be on antihypertensive, lipid-lowering, or antidiabetic medication, and displayed higher average values of key vascular risk factors, including blood pressure, lipid traits, and glycosylated hemoglobin. Furthermore, individuals with hepatic steatosis had a higher left atrial diameter and left ventricular mass than individuals without hepatic steatosis (Table 1) .
Association Between Hepatic Steatosis and Aortic Valve Sclerosis
Individuals with hepatic steatosis had a worse cardiovascular risk profile and a higher prevalence of aortic valve sclerosis compared with those without this condition (36.8% versus 28.4%; P<0.001; Table 1 ). The unadjusted odds ratio (OR) for the association between hepatic steatosis and aortic valve sclerosis was 1.47 (95% confidence interval [CI], 1.23-1.76; P<0.001). Consistently, in age-and sex-adjusted models, the OR for the association was 1.46 (95% CI, 1.19-1.79; P<0.001; Table 2 ). This association was attenuated on further adjustment for waist-to-height ratio, smoking, alcohol consumption, and physical activity (model 2; Table 2 ) and after adjustment for several potential confounding factors, including systolic blood pressure, antihypertensive medication, total/high-density lipoprotein cholesterol ratio, lipid-lowering medication, glycosylated hemoglobin, antidiabetic medication, antiplatelet medication, and estimated glomerular filtration rate (OR, 1.33; 95% CI, 1.06-1.66; P=0.014; model 3; Table 2 ). When we excluded participants with diabetes mellitus (n=367) and heavy alcohol consumption (n=153) or any of the previous conditions, the results remained essentially unchanged ( We repeated our analyses using the modified definition of hepatic steatosis based on ultrasonographic evidence of hepatic steatosis and increased serum alanine aminotransferase levels (Table 3) . Individuals with ultrasonographic evidence of hepatic steatosis (US+ in Table 3 ) had increased odds of aortic valve sclerosis, and this association was stronger and reached statistical significance, particularly in those with ultrasonographic evidence of hepatic steatosis and increased alanine aminotransferase levels (OR, 1.37; 95% CI, 1.004-1.86; P=0.047 in multivariable-adjusted models; model 3; Table 3 ). When we restricted the analyses to participants without diabetes mellitus and without heavy alcohol consumption, we obtained essentially the same results ( Table III in the online-only Data Supplement). Furthermore, we assessed the association between hepatic steatosis and aortic valve sclerosis stratified by age (< and ≥65 years). The multivariableadjusted OR for the association between hepatic steatosis and aortic valve sclerosis (model 3) was 1.41 (95% CI, 1.01-1.97; P=0.047) for individuals aged <65 years (n=1371) and 1.16 (95% CI, 0.85-1.57; P=0.340) for individuals aged ≥65 years (n=841; Table 4 ). The association between hepatic steatosis and aortic valve sclerosis did not differ statistically significantly by sex and was not modified by alcohol consumption (P values for interaction >0.1). However, in Table IV in the online-only Data Supplement we show the sex-stratified analyses for descriptive reasons. In Table V in the online-only Data Supplement, we used body mass index as a potential cofounder instead of waist-to-height ratio.
After further adjustment for inflammatory markers, including high-sensitive C-reactive protein (hs-CRP), ferritin, and white blood cells, the OR decreased from 1.33 to 1.32 in the overall sample (model 4; Table 2 ). A slight reduction in the OR on adjustment for these inflammatory markers was observed in models after excluding participants with diabetes mellitus and heavy alcohol consumption (Tables II and III in the onlineonly Data Supplement) and when using the modified definition of hepatic steatosis based on ultrasonographic evidence of hepatic steatosis and increased serum alanine aminotransferase ( Table 3 and Table III in the online-only Data Supplement).
Discussion
In a sample from the general population (n=2212), we observed an association between the presence of hepatic steatosis and aortic valve sclerosis. This association persisted after adjustment for multiple cardiovascular and metabolic risk factors.
In the Context of Published Literature
Our observation is in line with a growing body of evidence indicating that hepatic steatosis is correlated with cardiometabolic risk factors 2,3 and subclinical and clinical manifestations of cardiac and vascular disease. 1,7-9 A recent review, which included population-based and hospital-based case-control and cohort studies, 9 revealed a strong and highly significant association of augmented intima media thickness and higher prevalence of carotid plaques with nonalcoholic fatty liver disease. In line with these observations, a higher prevalence of calcified and noncalcified coronary plaques was found in individuals with hepatic steatosis compared with age-and sex-matched controls. 10 Interestingly, the latter association remained significant on adjustment for the metabolic syndrome and hs-CRP. 10 Furthermore, patients with hepatic steatosis had higher left ventricular mass and a lower early (E) to late (A) ventricular filling velocities ratio compared with age-and sex-matched controls, suggesting that hepatic steatosis also affects left ventricular structure and diastolic function. 24 Besides these associations with subclinical markers of cardiac and vascular remodeling, hepatic steatosis was associated with an increased risk for clinical CVD end points, including coronary heart disease, ischemic stroke, as well cardiovascular mortality in patients with type 2 diabetes mellitus. 7
Potential Mechanisms for the Observed Association
Hepatic steatosis and aortic valve sclerosis are both correlated with cardiovascular and metabolic risk factors. 2, 15, [25] [26] [27] Nonalcoholic fatty liver disease is considered a feature of the metabolic syndrome, 4,28 a constellation of risk factors, which also adversely affects the development of aortic valve sclerosis and portends an increased risk of valve replacement or death. 29 Thus, one interpretation of the observed association is that fatty liver disease can be regarded as a marker of increased cardiometabolic risk without a direct causal role in the development of atherosclerosis and calcification. In line with this concept, the association between nonalcoholic fatty liver disease and CVD was rendered nonsignificant on adjustment for metabolic syndrome in patients with type 2 diabetes mellitus. 4 However, in our analyses, the association between hepatic steatosis and aortic valve sclerosis persisted after adjustment for several metabolic and cardiovascular risk factors, including age, sex, waist-to-height ratio, smoking, alcohol consumption, physical activity, systolic blood pressure, antihypertensive medication, total/high-density lipoprotein cholesterol ratio, antilipidemic medication, glycosylated hemoglobin, antidiabetic medication, antiplatelet medication, estimated glomerular filtration rate, hs-CRP, serum ferritin levels, and white blood cells. Furthermore, the association between hepatic steatosis and aortic valve sclerosis was essentially unaltered after excluding participants with diabetes mellitus and heavy alcohol consumption. This suggests that additional mechanisms, beyond classic metabolic and cardiovascular risk factors, could, in part, be responsible for the observed association.
The mechanisms that may explain the possible increased cardiovascular risk in individuals with prevalent hepatic steatosis are complex and likely interdependent. One possible mechanism is chronic inflammation. It is well established that liver produces inflammatory markers (eg, interleukin-6, tumor necrosis factor-α) and that the release of such cytokines is increased in the presence of fat infiltration in the liver. 1 In line with this concept, individuals with nonalcoholic fatty liver disease (including individuals with steatohepatitis and simple steatosis, n=85) demonstrated increased circulating levels of hs-CRP compared with controls (n=160), after accounting for obesity, age, sex, smoking, insulin resistance, and metabolic syndrome. 30 Inflammatory markers are thought to contribute to the underlying hepatic disease/steatosis progression, as well as to accelerated atherosclerosis, 1 and, therefore, represent one potential mechanism for the development of calcification of the aortic valve. Indeed, histological examinations after heart valve surgery underscore the concept that aortic valve sclerosis is, in part, an inflammatory condition with resemblances to classic atherosclerotic lesions. 11, 31 Individuals submitted to surgical valve replacement resulting from aortic valve stenosis, compared with surgical controls, presented elevated plasma levels of systemic markers of inflammation, such as hs-CRP, erythrocyte sedimentation rate, and fibrinogen. 32 To assess the hypothesis that inflammation may be a putative mechanism linking hepatic steatosis to aortic valve sclerosis, we added hs-CRP, ferritin, and white blood cells as markers of systemic inflammation to our regression model. The additional adjustment for these inflammatory markers very slightly reduced the association between hepatic steatosis and aortic valve sclerosis in the entire sample as well as in the sample excluding individuals with diabetes mellitus and heavy alcohol consumption. These data are consistent with the concept that inflammation may have a small influence on the association between hepatic steatosis and aortic valve sclerosis, but that it is probably not the main driver of this association. There are other potential pathophysiological pathways that could also be responsible for the association between hepatic steatosis and aortic valve sclerosis, including, for example, insulin resistance. It is still under debate whether hepatic steatosis is a cause of insulin resistance or a secondary result of this condition. In a small clinical sample, 33 individuals with hepatic steatosis had a decline in their insulin clearance (as assessed by euglycemic hyperinsulinemic clamp) and elevated levels of fasting plasma insulin compared with nonobese nondiabetic controls without liver disease. However, the small samples size and the cross-sectional design of that latter study do not allow drawing inferences regarding the temporal ordering of exposures and outcomes. In our statistical model, we adjusted for glycosylated hemoglobin levels and the use of antidiabetic medication, with little effect on our results. Furthermore, when we excluded participants with prevalent diabetes mellitus and heavy alcohol consumption, the results were essentially unchanged, providing evidence that clinical diabetes mellitus did not substantially affect the results. Unfortunately, no specific measure of insulin resistance was available in our sample, such as fasting plasma insulin and glucose, to calculate the Homeostatic Model Assessment index. In secondary analyses, when stratifying the sample by age 65 years, we observed that the association between hepatic steatosis and aortic valve sclerosis was not statistically significant in individuals aged ≥65 years, whereas it was numerically stronger and statistically significant in younger individuals. This could be explained by the higher and more uniform prevalence of visceral obesity 34 and other metabolic and cardiovascular risk factors in the elderly so that the relative contribution of hepatic steatosis to aortic valve sclerosis is smaller than in the younger age group, where, if present, hepatic steatosis could be more harmful and a stronger marker of or contributing cause to cardiovascular morbidity.
Study Limitations
Some limitations of this study merit consideration. First, this study was conducted in middle-aged Europeans; it is unknown whether our findings are also applicable to other ethnicities and age groups. Second, our data were obtained from a crosssectional study so that we cannot draw any causal inferences regarding cause and effect. A longitudinal study with multiple repeated measurements would also be helpful to study further mediating factors in this association of hepatic steatosis and aortic valve sclerosis. Specifically, we cannot rule out that hepatic steatosis could be the result and not the precursor of an inflammatory process, as has been suggested in some experimental settings. 35 Third, liver biopsy is considered the best method to diagnose hepatic steatosis. However, for general population research, liver biopsies are not feasible. Fourth, a nonfasting venous blood sample was obtained from all participants (so adjustment for either fasting glucose or status of impaired fasting glucose and metabolic syndrome was not possible). Finally, although we have included several metabolic and cardiovascular risk factors in our multivariable model, we cannot rule out that residual confounding, categorization of several exposures or confounding variables, or mediation between other factors could be an explanation for our observation. Specifically, some of the variables that we used were not continuous but rather categorical (smoking, physical activity, antihypertensive, antilipemic, antidiabetic, and antiplatelet medication), which leads to some reduction in the precision of the adjustment (compared with modeling these traits continuously). Besides that, there are some pathophysiological pathways, through unmeasured confounders, for example, additional markers of inflammation or metabolic alterations, that could partially explain the association between hepatic steatosis and aortic valve sclerosis, but for which we had no precisely measured variable in our sample.
Conclusions
Our findings add evidence that hepatic steatosis and aortic valve sclerosis are interrelated conditions, in part independent from classic CVD risk factors. The release of proatherogenic substances by the steatotic liver or its contribution to insulin resistance and dyslipidemia may contribute to the development of calcification and sclerosis of the aortic valve. These findings warrant confirmation in independent samples, and the precise mechanisms underlying this association require additional investigations. Furthermore, future studies should address whether changes in the metabolic risk profile of individuals with hepatic steatosis affect the progression of aortic valve sclerosis.
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Fat accumulation in the liver, referred to as hepatic steatosis, is a common finding in developed societies, with a prevalence of ≈30% in adults of the overall population. There is accumulating evidence suggesting that hepatic steatosis either directly contributes to cardiovascular morbidity or subclinical cardiovascular disease or is a marker of increased cardiovascular risk. Sclerosis of the aortic valve is characterized by progressive fibrosis and, at a later stage, calcification of the aortic valve leaflet; its physiopathology shares some parallels with the general atherosclerosis process. Our analyses provide evidence that hepatic steatosis is associated with aortic valve sclerosis and that this association is partially independent from classic cardiovascular disease risk factors. The release of proatherogenic substances by the steatotic liver or its contribution to insulin resistance and dyslipidemia may contribute to the development of calcification and sclerosis of the aortic valve. The precise mechanisms underlying this association require additional investigations.
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